Guidance, NICE advice and quality standards in development | Guidance

Showing 161 to 170 of 379

Sort by

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Insulin efsitora alfa for treating type 2 diabetes [ID6499]	Technology appraisal guidance	22 October 2026
Insulin icodec for treating type 2 diabetes [ID6175]	Technology appraisal guidance	TBC
Intrathecal onasemnogene abeparvovec for treating spinal muscular atrophy in people 2 years and over [ID6556]	Technology appraisal guidance	26 August 2026
Ipatasertib with fulvestrant for treating oestrogen-receptor positive HER2-negative advanced breast cancer after CDK 4/6 and aromatase inhibitor treatment [TSID12194]	Technology appraisal guidance	TBC
Iptacopan for treating complement 3 glomerulopathy in people 12 to 18 years [ID6738]	Technology appraisal guidance	TBC
Iptacopan for treating primary IgA nephropathy [ID6640]	Technology appraisal guidance	TBC
Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma [review of TA658] [ID4067]	Technology appraisal guidance	TBC
Ixazomib citrate for maintenance treatment of untreated multiple myeloma in people who cannot have autologous stem cell transplant [ID2706]	Technology appraisal guidance	TBC
Ixekizumab for treating enthesitis-related arthritis and juvenile psoriatic arthritis in people 2 to 17 years [ID6590]	Technology appraisal guidance	TBC
Lacosamide for adjunctive treatment of primary generalised tonic-clonic seizures in epilepsy [ID1687]	Technology appraisal guidance	TBC